/PEXAB.ST

PEXAB.ST Stock - Pexa AB

Q: What is the analyst price target for PEXAB.ST?

Analyst price target information is not currently available for PEXAB.ST.

Q: What is PEXAB.ST's market cap?

Market capitalization information is not currently available for PEXAB.ST.

Healthcare|Medical - Specialties|STO

$0.25-0.40%

$0.00 (-0.40%) • Feb 12

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $0.27

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for PEXAB.ST

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta1.02

52W High$0.55

52W Low$0.16

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	$719,619	$2.02M	$6.03M	$2.16M	$673,610
Gross Profit	$-10,156,425	$-8,519,452	$-4,442,028	$-6,817,129	$-7,096,820
Gross Margin	-1411.4%	-422.8%	-73.7%	-315.4%	-1053.6%
Operating Income	$-10,451,285	$-8,519,452	$-4,442,030	$-7,639,270	$-7,918,970
Net Income	$-10,162,729	$-8,043,568	$-4,305,353	$-7,758,938	$-7,912,924
Net Margin	-1412.2%	-399.1%	-71.4%	-359.0%	-1174.7%
EPS	$-0.14	$-0.15	$-0.11	$-0.29	$-0.39

Company Overview

Pexa AB engages in the development and commercialization of technology in the field of respiratory medicine. It provides lung researchers with a simple and non-invasive method for collection of microscopic particles, potential biomarkers for diseases in the small airways. The company was founded by Anna-Carin Olin in 2010 and is headquartered in Gothenburg, Sweden.

Visit Website